Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,121 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control comparison Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

NCT02343458
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
44
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 21, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB019602, Placebo, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

NCT02004262
View directory record Official record
Conditions
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Interventions
GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide
Biological · Drug
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns

NCT06329388
View directory record Official record
Conditions
Growth Disorders, Dietary Exposure, Child Development, Bone Development Abnormal, Body Weight, Child Malnutrition
Interventions
TruHeight Growth Protein Shake
Dietary Supplement
Lead sponsor
TruHeight Vitamins
Industry
Eligibility
4 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Effectiveness of Adductor Canal Pain Catheters Following Total Knee Arthroplasty

NCT05053087
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Ropivacaine Continuous Infusion, Ropivacaine Intermittent Bolus, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alcohol Health Education With Personalized Feedback Boosters

NCT03440463
View directory record Official record
Conditions
College Student Drinking
Interventions
e-checkup to go, Norms-only booster, Norms-plus-Strategies booster
Behavioral
Lead sponsor
Abby Braitman
Other
Eligibility
18 Years to 24 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
24
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03439072
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Lilly Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab Injection, Xolair Prefilled Syringe
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 21, 2026, 10:22 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Effect of Transcutaneous Magnetic Stimulation on Acute Pain.

NCT03777137
View directory record Official record
Conditions
Pain Perception
Interventions
TMS (Rapid2, Magstim Corp)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

NCT00838903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, sitagliptin, glimepiride, metformin, placebo albiglutide, placebo sitagliptin, placebo glimepiride
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
317
States / cities
Birmingham, Alabama • Dothan, Alabama • Hueytown, Alabama + 254 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 21, 2026, 10:22 PM EDT
Recruiting No phase listed Observational

A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension

NCT06040827
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Total Knee Arthroplasty
Device
Lead sponsor
Canary Medical
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Timeline
2023 – 2028
U.S. locations
7
States / cities
Fayetteville, Arkansas • Tampa, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

NCT02938494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, Tazorac Cream, Vehicle Lotion, Vehicle Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Encinitas, California • Fremont, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Biological · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 21, 2026, 10:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

NCT03065465
View directory record Official record
Conditions
Upper Gastrointestinal Hemorrhage
Interventions
Over-the-scope hemoclipping device, Standard endoscopic treatment
Device · Other
Lead sponsor
CURE Digestive Diseases Research Center
Other
Eligibility
18 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows

NCT01249170
View directory record Official record
Conditions
Communication
Interventions
First year program, Control comparison
Behavioral · Other
Lead sponsor
Jennifer McCallister MD
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

NCT00170469
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
AVA, rPA vaccine containing alhydrogel
Biological
Lead sponsor
PharmAthene UK Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
16
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Sep 21, 2026, 10:22 PM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
54
States / cities
Birmingham, Alabama • Tucson, Arizona • Inglewood, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

NCT03648996
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperuricemia
Interventions
Low-fructose diet, isocaloric, Allopurinol, Placebo, Low-fructose, hypocaloric
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Dose of Vestibular Rehabilitation for Vestibular Hypofunction

NCT04851184
View directory record Official record
Conditions
Vestibular Disorder
Interventions
Gaze stabilization Exercises using Virtual Reality Device, Gaze stabilization non-instrumented
Device · Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 74 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Civamide Patch Safety, Tolerability and PK Study

NCT00758433
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zucapsaicin, Placebo patch
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Port Chester, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 21, 2026, 10:22 PM EDT
Terminated Not applicable Interventional

Trial of Feedback on Blood Use

NCT02232568
View directory record Official record
Conditions
Compliance With Restrictive RBC Transfusion Guideline
Interventions
Feedback
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 21, 2026, 10:22 PM EDT